Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paclitaxel + carboplatin + amifostine
- Development stage
- Unknown
- Lead developer
- Baptist Health South Florida
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
This drug entry refers to a combination chemotherapy and radioprotectant regimen consisting of paclitaxel, carboplatin, and amifostine, evaluated by Baptist Health South Florida for the treatment of inoperable stage II-IIIB non-small cell lung cancer (NSCLC). Paclitaxel is a taxane that stabilizes microtubules, preventing cell division, while carboplatin is a platinum-based antineoplastic agent that causes DNA cross-linking. Amifostine is included as a cytoprotective agent to reduce mucosal toxicity associated with the concurrent high-dose 3D conformal hyperfractionated radiation therapy (3D-CHRT). The regimen aims to maximize tumor control through dose-escalated radiation while minimizing damage to normal tissues.
- Brand names
- TaxolParaplatinEthyol
- Other names
- Paclitaxel/Carboplatin/Amifostine regimen3D-CHRT combination therapy
02
Targets
TUBB (Tubulin (alpha and beta subunits))DNA
Beyond the preview
Go deeper on paclitaxel + carboplatin + amifostine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paclitaxel + carboplatin + amifostine.